PharmaEssentia Corporation (TPEx: 6446) is a fully integrated biotech company based in Taiwan. The company engages in innovation, clinical development, production and manufacturing of new drugs, and global commercialization. PharmaEssentia utilized its self-developed PEG molecule and PEGylation technology platform to produce a long-acting protein drug with the advantages of prolonged efficacy time and the simplest compound. The innovative long-acting interferon P1101 (Ropeginterferon alfa-2b) invented by PharmaEssentia has been approved by the agencies in European Union, Taiwan, Switzerland, Israel, and South Korea for the treatment of Polycythemia Vera (PV) since 2019. In 2021, P1101 is expected to be approved in the United States. PharmaEssentia is currently conducting the multi-country and multi-center Phase III clinical trials of P1101 for the treatment of Essential Thrombocythemia (ET) globally. After completion of the Phase III trials, the company will submit new drug application (NDA) in various countries. The company’s Taichung plant has completed commercial mass production and was GMP certified by TFDA, EMA, and South Korea MFDS. In addition, the company’s filled and finished plant was also GMP and GDP certified by TFDA.